-
1
-
-
0030933395
-
Natural history of liver fibrosis progression in patients with chronic hepatitis C. The OBSVIRC, METAVIR, CLINIVIR, and DOSVIRC groups
-
Poynard T., Bedossa P., Opolon P. Natural history of liver fibrosis progression in patients with chronic hepatitis C. The OBSVIRC, METAVIR, CLINIVIR, and DOSVIRC groups. Lancet 1997, 349:825-832.
-
(1997)
Lancet
, vol.349
, pp. 825-832
-
-
Poynard, T.1
Bedossa, P.2
Opolon, P.3
-
3
-
-
0033932001
-
Recovery, persistence, and sequelae in hepatitis C virus infection: a perspective on long-term outcome
-
Alter H.J., Seeff L.B. Recovery, persistence, and sequelae in hepatitis C virus infection: a perspective on long-term outcome. Seminars in Liver Disease 2000, 20:17-35.
-
(2000)
Seminars in Liver Disease
, vol.20
, pp. 17-35
-
-
Alter, H.J.1
Seeff, L.B.2
-
4
-
-
17344370538
-
Prognosis of chronic hepatitis C: results of a large prospective cohort study
-
Niederau C., Lange S., Heintges T., et al. Prognosis of chronic hepatitis C: results of a large prospective cohort study. Hepatology 1998, 28:1687-1695.
-
(1998)
Hepatology
, vol.28
, pp. 1687-1695
-
-
Niederau, C.1
Lange, S.2
Heintges, T.3
-
5
-
-
15644380122
-
Long-term histologic improvement and loss of detectable intrahepatic HCV RNA in patients with chronic hepatitis C and sustained response to interferon-alpha therapy
-
Marcellin P., Boyer N., Gervais A., et al. Long-term histologic improvement and loss of detectable intrahepatic HCV RNA in patients with chronic hepatitis C and sustained response to interferon-alpha therapy. Annals of Internal Medicine 1997, 127:875-881.
-
(1997)
Annals of Internal Medicine
, vol.127
, pp. 875-881
-
-
Marcellin, P.1
Boyer, N.2
Gervais, A.3
-
6
-
-
84870454347
-
Treatment indication and response to standard of care with peginterferon and ribavirin in acute and chronic HCV infection
-
Feld J.J. Treatment indication and response to standard of care with peginterferon and ribavirin in acute and chronic HCV infection. Best Practice & Research Clinical Gastroenterology 2012, 26:429-444.
-
(2012)
Best Practice & Research Clinical Gastroenterology
, vol.26
, pp. 429-444
-
-
Feld, J.J.1
-
7
-
-
65449152185
-
Telaprevir with peginterferon and ribavirin for chronic HCV genotype 1 infection
-
McHutchison J.G., Everson G.T., Gordon S.C., et al. Telaprevir with peginterferon and ribavirin for chronic HCV genotype 1 infection. New England Journal of Medicine 2009, 360:1827-1838.
-
(2009)
New England Journal of Medicine
, vol.360
, pp. 1827-1838
-
-
McHutchison, J.G.1
Everson, G.T.2
Gordon, S.C.3
-
8
-
-
65449171953
-
Telaprevir and peginterferon with or without ribavirin for chronic HCV infection
-
Hezode C., Forestier N., Dusheiko G., et al. Telaprevir and peginterferon with or without ribavirin for chronic HCV infection. New England Journal of Medicine 2009, 360:1839-1850.
-
(2009)
New England Journal of Medicine
, vol.360
, pp. 1839-1850
-
-
Hezode, C.1
Forestier, N.2
Dusheiko, G.3
-
9
-
-
77956268467
-
Efficacy of boceprevir, an NS3 protease inhibitor, in combination with peginterferon alfa-2b and ribavirin in treatment-naive patients with genotype 1 hepatitis C infection (SPRINT-1): an open-label, randomised, multicentre phase 2 trial
-
Kwo P.Y., Lawitz E.J., McCone J., et al. Efficacy of boceprevir, an NS3 protease inhibitor, in combination with peginterferon alfa-2b and ribavirin in treatment-naive patients with genotype 1 hepatitis C infection (SPRINT-1): an open-label, randomised, multicentre phase 2 trial. Lancet 2010, 376:705-716.
-
(2010)
Lancet
, vol.376
, pp. 705-716
-
-
Kwo, P.Y.1
Lawitz, E.J.2
McCone, J.3
-
10
-
-
84865560854
-
Cost-effectiveness of boceprevir or telaprevir for untreated patients with genotype 1 chronic hepatitis C
-
Cammà C., Petta S., Enea M., et al. Cost-effectiveness of boceprevir or telaprevir for untreated patients with genotype 1 chronic hepatitis C. Hepatology 2012, 56:850-860.
-
(2012)
Hepatology
, vol.56
, pp. 850-860
-
-
Cammà, C.1
Petta, S.2
Enea, M.3
-
11
-
-
84858432382
-
A practical guide for the use of boceprevir and telaprevir for the treatment of hepatitis C
-
Jacobson I.M., Pawlotsky J.M., Afdhal N.H., et al. A practical guide for the use of boceprevir and telaprevir for the treatment of hepatitis C. Journal of Viral Hepatitis 2012, 19:1-26.
-
(2012)
Journal of Viral Hepatitis
, vol.19
, pp. 1-26
-
-
Jacobson, I.M.1
Pawlotsky, J.M.2
Afdhal, N.H.3
-
12
-
-
84857368831
-
UK consensus guidelines for the use of the protease inhibitors boceprevir and telaprevir in genotype 1 chronic hepatitis C infected patients
-
Ramachandran P., Fraser A., Agarwal K., et al. UK consensus guidelines for the use of the protease inhibitors boceprevir and telaprevir in genotype 1 chronic hepatitis C infected patients. Alimentary Pharmacology and Therapeutics 2012, 35:647-662.
-
(2012)
Alimentary Pharmacology and Therapeutics
, vol.35
, pp. 647-662
-
-
Ramachandran, P.1
Fraser, A.2
Agarwal, K.3
-
13
-
-
0037179698
-
Peginterferon alfa-2a plus ribavirin for chronic hepatitis c infection
-
Fried M.W., Shiffman M.L., Reddy K.R., et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis c infection. New England Journal of Medicine 2002, 347:975-982.
-
(2002)
New England Journal of Medicine
, vol.347
, pp. 975-982
-
-
Fried, M.W.1
Shiffman, M.L.2
Reddy, K.R.3
-
14
-
-
1542378867
-
Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirn dose
-
Hadziyannis S.J., Sette J.R., Morgan T.R., et al. Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirn dose. Annals of Internal Medicine 2004, 140:346-355.
-
(2004)
Annals of Internal Medicine
, vol.140
, pp. 346-355
-
-
Hadziyannis, S.J.1
Sette, J.R.2
Morgan, T.R.3
-
15
-
-
0035934568
-
Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomized trial
-
Manns M.P., McHutchinson J.G., Gordon S.C., et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomized trial. Lancet 2001, 358:958-965.
-
(2001)
Lancet
, vol.358
, pp. 958-965
-
-
Manns, M.P.1
McHutchinson, J.G.2
Gordon, S.C.3
-
16
-
-
84867767288
-
Safety profile of standard- vs. high-dose peginterferon alfa-2a plus standard-dose ribavirin in HCV genotype 1/4 patients: pooled analysis from 5 randomized studies
-
Marcellin P., Roberts S.K., Reddy K.R., et al. Safety profile of standard- vs. high-dose peginterferon alfa-2a plus standard-dose ribavirin in HCV genotype 1/4 patients: pooled analysis from 5 randomized studies. Expert Opinion on Drug Safety 2012, 11:901-909.
-
(2012)
Expert Opinion on Drug Safety
, vol.11
, pp. 901-909
-
-
Marcellin, P.1
Roberts, S.K.2
Reddy, K.R.3
-
17
-
-
84870427882
-
Response guided therapy in patients with chronic hepatitis C - yesterday, today and tomorrow
-
Ferenci P. Response guided therapy in patients with chronic hepatitis C - yesterday, today and tomorrow. Best Practice & Research Clinical Gastroenterology 2012, 26:463-469.
-
(2012)
Best Practice & Research Clinical Gastroenterology
, vol.26
, pp. 463-469
-
-
Ferenci, P.1
-
18
-
-
79960453276
-
EASL clinical practice guidelines: management of hepatitis C virus infection
-
Craxì A. EASL clinical practice guidelines: management of hepatitis C virus infection. Journal of Hepatology 2011, 55:245-264.
-
(2011)
Journal of Hepatology
, vol.55
, pp. 245-264
-
-
Craxì, A.1
-
19
-
-
77958029477
-
Practice guidelines for the treatment of hepatitis C: recommendations from an AISF/SIMIT/SIMAST
-
Practice guidelines for the treatment of hepatitis C: recommendations from an AISF/SIMIT/SIMAST. Expert Opinion Meeting Digestive and Liver Disease 2010, 42:81-91.
-
(2010)
Expert Opinion Meeting Digestive and Liver Disease
, vol.42
, pp. 81-91
-
-
-
20
-
-
20544443172
-
Peginterferon alpha-2b and RBV for 12 vs. 24 weeks in HCV genotype 2 and 3
-
Mangia A., Santoro R., Minerva N., et al. Peginterferon alpha-2b and RBV for 12 vs. 24 weeks in HCV genotype 2 and 3. New England Journal of Medicine 2005, 35:2609-2617.
-
(2005)
New England Journal of Medicine
, vol.35
, pp. 2609-2617
-
-
Mangia, A.1
Santoro, R.2
Minerva, N.3
-
21
-
-
38649090068
-
Pegylated interferon alfa and RBV for 14 versus 24 weeks in patients with hepatitis C virus genotype 2 or 3 and rapid virological response
-
Dalgard O., Bjoro K., Ring-Larsen H., et al. Pegylated interferon alfa and RBV for 14 versus 24 weeks in patients with hepatitis C virus genotype 2 or 3 and rapid virological response. Hepatology 2008, 47:35-42.
-
(2008)
Hepatology
, vol.47
, pp. 35-42
-
-
Dalgard, O.1
Bjoro, K.2
Ring-Larsen, H.3
-
22
-
-
23244457832
-
PegInterferon alpha 2a (Pegasys) plus RBV (Copegus) for 16 or 24 weeks in patients with HCV genotpe 2 and 3 chronic hepatitis C
-
von Wagner H., Huber H., Berg T., et al. PegInterferon alpha 2a (Pegasys) plus RBV (Copegus) for 16 or 24 weeks in patients with HCV genotpe 2 and 3 chronic hepatitis C. Gastroenterology 2005, 129:522-527.
-
(2005)
Gastroenterology
, vol.129
, pp. 522-527
-
-
von Wagner, H.1
Huber, H.2
Berg, T.3
-
23
-
-
0041822106
-
Early virologic response to treatment with peginterferon alpha 2b plus Ribavirin in patients with chronic hepatitis C
-
Davis G.L. Early virologic response to treatment with peginterferon alpha 2b plus Ribavirin in patients with chronic hepatitis C. Hepatology 2003, 38:645-652.
-
(2003)
Hepatology
, vol.38
, pp. 645-652
-
-
Davis, G.L.1
-
24
-
-
79958816097
-
Rapid virological response is the most important predictor of sustained virological response across genotypes in patients with chronic hepatitis C virus infection
-
Fried M.W., Hadziyannis S.J., Shiffman M.L., et al. Rapid virological response is the most important predictor of sustained virological response across genotypes in patients with chronic hepatitis C virus infection. Journal of Hepatology 2011, 55:69-75.
-
(2011)
Journal of Hepatology
, vol.55
, pp. 69-75
-
-
Fried, M.W.1
Hadziyannis, S.J.2
Shiffman, M.L.3
-
25
-
-
84870533049
-
High sustained virologic response rates in rapid virologic response patients in the large real-world PROPHESYS cohort confirm results from randomized clinical trials
-
Marcellin P., et al. High sustained virologic response rates in rapid virologic response patients in the large real-world PROPHESYS cohort confirm results from randomized clinical trials. Hepatology 2012, 56:2039-2050.
-
(2012)
Hepatology
, vol.56
, pp. 2039-2050
-
-
Marcellin, P.1
-
26
-
-
23444460553
-
Predicting sustained virological responses in chronic hepatitis C patients treated with peginterferon alfa-2a (40 KD)/ribavirin
-
Ferenci P., Fried M.W., Schiffman M.L., et al. Predicting sustained virological responses in chronic hepatitis C patients treated with peginterferon alfa-2a (40 KD)/ribavirin. Journal of Hepatology 2005, 43:425-433.
-
(2005)
Journal of Hepatology
, vol.43
, pp. 425-433
-
-
Ferenci, P.1
Fried, M.W.2
Schiffman, M.L.3
-
27
-
-
33748494889
-
Short-term treatment duration for HCV-2 and HCV-3 infected patients
-
Andriulli A., Dalgard O., Bjøro K., et al. Short-term treatment duration for HCV-2 and HCV-3 infected patients. Digestive and Liver Disease 2006, 38:741-748.
-
(2006)
Digestive and Liver Disease
, vol.38
, pp. 741-748
-
-
Andriulli, A.1
Dalgard, O.2
Bjøro, K.3
-
28
-
-
61949212724
-
Determinants of relapse after a short (12 weeks) course of antiviral therapy and re-treatment efficacy of a prolonged course in patients with chronic hepatitis C virus genotype 2 or 3 infection
-
Mangia A., Minerva N., Bacca D., et al. Determinants of relapse after a short (12 weeks) course of antiviral therapy and re-treatment efficacy of a prolonged course in patients with chronic hepatitis C virus genotype 2 or 3 infection. Hepatology 2009, 49:358-363.
-
(2009)
Hepatology
, vol.49
, pp. 358-363
-
-
Mangia, A.1
Minerva, N.2
Bacca, D.3
-
29
-
-
38649090347
-
Individualized treatment duration for hepatitis C Genotype 1 patients: a randomized controlled trial
-
Mangia A., Minerva N., Bacca D., et al. Individualized treatment duration for hepatitis C Genotype 1 patients: a randomized controlled trial. Hepatology 2008, 47:43-50.
-
(2008)
Hepatology
, vol.47
, pp. 43-50
-
-
Mangia, A.1
Minerva, N.2
Bacca, D.3
-
30
-
-
68949183162
-
Individualized treatment strategy according to early viral kinetics in hepatitis C virus type 1-infected patients
-
Berg T., Weich V., Teuber G., et al. Individualized treatment strategy according to early viral kinetics in hepatitis C virus type 1-infected patients. Hepatology 2009, 50:369-377.
-
(2009)
Hepatology
, vol.50
, pp. 369-377
-
-
Berg, T.1
Weich, V.2
Teuber, G.3
-
31
-
-
80054846451
-
Improved response to pegylated-interferon alfa-2b and ribavirin by individualizing treatment for 24-72 weeks
-
Sarrazin C., Schwendy S., Moller B., et al. Improved response to pegylated-interferon alfa-2b and ribavirin by individualizing treatment for 24-72 weeks. Gastroenterology 2011, 141:1656-1664.
-
(2011)
Gastroenterology
, vol.141
, pp. 1656-1664
-
-
Sarrazin, C.1
Schwendy, S.2
Moller, B.3
-
32
-
-
78851469540
-
Pre-treatment prediction of response to pegylated-interferon plus ribavirin for chronic hepatitis C using genetic polymorphism in IL28B and viral factors
-
Kurosaki M., Tanaka Y., Nishida N., et al. Pre-treatment prediction of response to pegylated-interferon plus ribavirin for chronic hepatitis C using genetic polymorphism in IL28B and viral factors. Journal of Hepatology 2011, 54:439-448.
-
(2011)
Journal of Hepatology
, vol.54
, pp. 439-448
-
-
Kurosaki, M.1
Tanaka, Y.2
Nishida, N.3
-
33
-
-
78650973933
-
IL28B genomic-based treatment paradigms for patients with chronic hepatitis c infection: the future of personalized HCV therapies
-
Clark P.J., Thompson A.J., McHutchison J. IL28B genomic-based treatment paradigms for patients with chronic hepatitis c infection: the future of personalized HCV therapies. American Journal of Gastroenterology 2011, 106:38-45.
-
(2011)
American Journal of Gastroenterology
, vol.106
, pp. 38-45
-
-
Clark, P.J.1
Thompson, A.J.2
McHutchison, J.3
-
34
-
-
84925580987
-
An IL28B polymorphism determines treatment response of hepatitis C virus genotype 2 or 3 patients who do not achieve a rapid virologic response
-
Mangia A., Thompson A.J., Santoro R., et al. An IL28B polymorphism determines treatment response of hepatitis C virus genotype 2 or 3 patients who do not achieve a rapid virologic response. Gastroenterology 2010, 139:821-827.
-
(2010)
Gastroenterology
, vol.139
, pp. 821-827
-
-
Mangia, A.1
Thompson, A.J.2
Santoro, R.3
|